PTCT

#2389
PTC Therapeutics, Inc. - Common Stock
73.8 5 USD
+3.94%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
73.85
73.85
Range Annuel
44.17
87.50
Changement quotidien
+3.94%
Changement Mensuel
+13.98%
Evolution sur 6 mois
-11.23%
Changement Annuel
+50.99%
Clôture Précédente
71.0 5
Open
73.8 5
Low
73.8 5
High
73.8 5
Volume
158
Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques
Trimestriel Annuel
  • Market Capitalization 612.58 M
  • Employee 991
  • Founded 1998
  • CEO Matthew B. Klein
  • Website www.ptcbio.com
  • Headquarter Delaware, United States
  • FIGI BBG000QT15P7
  • Industry Biotechnologies
Chiffre d'affaires total
Résultat net
Bénéfice par action de base (BPA de base)
Dette totale
Flux de trésorerie disponible
Trésorerie et équivalents de trésorerie
ratio cours/bénéfice
9.76
ratio cours/chiffre d'affaires
3.88

PTC Therapeutics, Inc. - Common Stock

PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control mechanisms in orphan diseases. In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019.

Nouvelles